MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, today announced that Prof. Dr. med. Steffen Stürzebecher, MD, PhD has been appointed Chief Medical Officer (CMO) effective immediately.

Steffen Stürzebecher has been advising MetrioPharm since September 2025 as Senior Development Advisor. In this role, he has particularly supported the company in the further development of its clinical and medical strategy and in key development activities.

Thomas Christély, Chief Executive Officer of MetrioPharm AG, welcomes the new addition: "We are delighted to welcome Steffen Stürzebecher as MetrioPharm's Chief Medical Officer. Steffen has successfully developed therapeutics through to approval in leading management positions at Schering, Glenmark Pharmaceuticals and the Grünenthal Group, among others. His extensive expertise in setting up global development programs will be invaluable in advancing MP1032 through to market approval."

Steffen Stürzebecher adds: “MetrioPharm has a promising pipeline of potential therapeutic uses of MP1032 and a highly committed team. As CMO, I look forward to further refining the clinical and medical strategy and implementing the next steps in the development.”

Profile: Prof. Steffen Stürzebecher, MD, PhD
Steffen Stürzebecher has more than 40 years of experience as a drug developer in the pharmaceutical industry. He brings management responsibility from various companies as well as many years of expertise in clinical development and medical strategy. Until its acquisition by Bayer in 2006, Prof. Stürzebecher held senior positions in clinical development at Schering AG and was subsequently responsible for clinical development as President Clinical R&D / CMO at Glenmark Pharmaceuticals and as Head of Development and later as CMO at Grünenthal Group, respectively.

Prof. Steffen Stürzebecher is a board-certified pharmacologist and toxicologist and an honorary professor at the University of Applied Sciences (HTW) Berlin. He received his doctorate from the Free University of Berlin and completed his postdoctoral research at the National Institutes of Health (NINDS, Neuroimmunology Branch).